ehealth radio network
Oncotarget Podcast Named Among Top-ten Open-access Podcasts of 2020

Oncotarget Podcast Named Among Top-ten Open-access Podcasts of 2020

May 2, 2020

 

oncotarget-logo-square.jpeg

 

Mr. Ryan James Jessup, the Director of External & Legal Affairs for Impact Journals, the publishing house of Oncotarget joins eHealth Radio and the Health News Channel.


Listen to interview with host Eric Michaels and guest Ryan James Jessup discuss the following:

  1. Oncotarget was just recently named in the top ten open-access podcasts for 2020 by player.fm?
  2. Tell us a little about Oncotarget if you would.
  3. Now how do you distinguish Oncotarget’s podcast from every other cancer podcast out there?
  4. Oncotarget has been the largest cancer research journal for half a decade...talk to us more in that regard.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial Introducing OncoTarget.

 

 oncotarget-logo-square.jpeg

 

Website: www.Oncotarget.com

Social Media Links:
Twitter: www.twitter.com/oncotarget 
Facebook: www.facebook.com/oncotarget

Shifting the Melanoma Detection Landscape

Shifting the Melanoma Detection Landscape

April 24, 2020

 

jdobak-headshotDMTK.jpg

 

Dr. John Dobak, the President & CEO of DermTech, the leading genomics company in dermatology that is creating a new category of medicine, precision dermatology, enabled their non-invasive skin genomics platform joins eHealth Radio and the Dermatology and Health News Channels.


Listen to interview with host Eric Michaels and guest Dr. John Dobak discuss the following:

  1. Precision medicine is a leading innovation. Can you tell us about Precision Dermatology and what that means?
  2. What is the value of genomics in dermatology?
  3. How does this non-invasive test have the potential to shift the melanoma detection landscape?
  4. How does the DermTech PLA work?
  5. Are you adapting to the shift towards tele-medicine within the current environment? 6. What is next for DermTech? Are there other applications of this technology?

Dr. John Dobak, MD, has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.

DermTech_Patch_Logo_Gray_WhiteBackground.jpg

Website: dermtech.com

Social Media Links:
Twitter: twitter.com/DermTech 
Instagram: instagram.com/dermtech 
Facebook: facebook.com/dermtech 
Linkedin: linkedin.com/company/dermtech

Platelet Activation and where it comes from

Platelet Activation and where it comes from

November 29, 2019

 

BillDubiel.png

 

Bill Dubiel, CEO of LightInterga Technologies maker of the ThromboLUX system, a simple 5-minute test that tells you the platelet activation status of a platelet bag, and lets you transfuse with confidence joins eHealth Radio and the Health News Channel.

 

Listen to interview with host Eric Michaels & guest Bill Dubiel discuss the following:

  1. What is platelet activation and what it the implication to transfusions?  
  2. Tell us about the platelet transfusion studies you have conducted and what the results show?
  3. How does the ThromboLUX test answer the question of platelet activation status? 
  4. Your studies suggest that by giving resting platelets to cancer patients they have better outcomes? Why?  
  5. Where does platelet activation come from and can it be prevented?
  6. Do you have any early users of the product and what could patients or medical professionals do to find out more about the technology?

Bill Dubiel is the President and CEO of LightIntegra Technologies, bringing more the 30 years of Healthcare experience with his last 10 years specifically helping medical device start-ups through the commercial buildout and product launch.

Previously, Bill was Chief Commercial Officer at PGDx and CyVek responsible for building a commercial organization to launch novel products into the global market. Bill also held executive sales, marketing, and service leadership positions at Ventana, Roche, Bayer and Chiron Diagnostics. Bill holds a BS from Rutgers University and an MBA from Phoenix University.


Websites: www.thrombolux.com  | www.lightintegra.com

Social Media Links:
Facebook: facebook.com/Thrombolux 
Twitter: @ThromboLUX

Transforming Lives with RNAi Technology

Transforming Lives with RNAi Technology

November 11, 2019

 

MichaelMolyneaux_FINAL.png

 

Dr. Michael Molyneaux, Chief Medical Officer of Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases joins eHealth Radio and the Cancer Information and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Dr. Michael Molyneaux discuss the following:

  1. Can you tell us about your background?
  2. What is Sirnaomics? Can you provide us with a background of the company and its current disease indication focus?
  3. What are some available treatments for non-melanoma skin cancer?
  4. How are RNA-based therapeutics different than DNA-based medicine?
  5. What are some drawbacks to RNAi-based therapy?
  6. What is Sirnaomics doing to address these challenges?
  7. What should people keep in mind when thinking about cancer treatment?

Dr. Michael Molyneaux, M.D., MBA & Chief Medical Officer of Sirnaomics brings a unique background with 20 years of experience in clinical medicine and direct patient care combined with 15 years of experience in clinical trial development. Mike is a board certified Medical Doctor and has completed his MBA. He was previously the CMO of Macrocure, a late stage clinical company that completed successful IPO in fall of 2014. Mike’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for Global Clinical Operations, Regulatory Affairs, and Medical Affairs. Mike is also a member of the Sirnaomics Board of Directors.

 

Sirnaomics_LOGO.jpg

Website: https://sirnaomics.com

Social Media Links:
LinkedIn: linkedin.com/company/sirnaomics-inc 
Facebook: facebook.com/sirnaomics

Harnessing the Immune System to Fight Cancer

Harnessing the Immune System to Fight Cancer

October 4, 2019

 

Bellicum_Rick_Fair_Headshot.jpg

 

Rick Fair, President & CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment joins eHealth Radio & the Cancer Information and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Rick Fair discuss the following:

  1. How does CAR-T cancer therapy compare to standard cancer treatments?
  2. What are some of the drawbacks to CAR-T Therapy?
  3. What is Bellicum doing to address these challenges?
  4. What should people keep in mind when thinking about cancer treatment?

Rick Fair is the President and CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment.

Prior to joining Bellicum, Mr. Fair served as the Senior Vice President, Head of Oncology Global Product Strategy at Genentech/Roche, where he led oncology product strategy and global commercialization. He also oversaw the global launch of five new cancer treatments, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine.

Prior to Genentech, Mr. Fair spent nine years at Johnson & Johnson, where he held leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.

 

BellicumPharmaceuticals_LOGO.png

 

Website: bellicum.com

Social Media Links:
Facebook: facebook.com/pages/Bellicum-Pharmaceuticals-Inc
Twitter: @BellicumPharma

One Woman’s Spiritual Journey: A Model for Anyone Seeking Unlimited Love and Strength

One Woman’s Spiritual Journey: A Model for Anyone Seeking Unlimited Love and Strength

December 30, 2018

 

VivianneNantel.jpg

 

Vivianne Nantel is a 21st century mystic and spiritual guide who overcame an abusive childhood, deep depression, advanced cancer and even a brush with death by harnessing the power of yoga and her own spiritual energy joins eHealth Radio and the Personal Development Channel. Vivianne is the author of: Becoming the Light: Realize Your True Enlightened Nature.

 

Listen to interview with host Eric Michaels and guest Vivianne Nantel discuss the following:

  1. What inspired you to write this book?
  2. Can you talk about your experience with advanced breast cancer, and how you used your own mind, body, and spirit to fight it?
  3. Please talk about some of the most profound moments you experienced on your journey. How did they stay with you, and influence you?
  4. How can this book help people suffering from chronic problems, such as depression or anxiety?

Vivianne Nantel is the real deal: a 21st century mystic and spiritual guide who overcame an abusive childhood, deep depression, advanced cancer and even a brush with death by harnessing the power of yoga and her own spiritual energy. She has been with Sadhguru, the Dalai Lama, Sri Sri Ravi Shankar and Yogiraj Gurunath, and became a gifted teacher of her own.

Her new book, Becoming the Light: Realize Your True Enlightened Nature (Greenleaf Book Group Press, August 2018), chronicles her incredible story. Based in California, she’s also a humanitarian, speaker, animal advocate, vocalist and also has appeared on on various television talk shows, including Earth Advocate and Bridging Heaven and Earth.

 

BecomingtheLight_COVER.jpg

 

Website: viviannenantel.com

Social Media Links:
Facebook: https://www.facebook.com/VivianneNantel
Instagram: https://www.instagram.com/viviannenantel
Twitter: https://twitter.com/VivianneNantel1


The views, ideas, thoughts and opinions expressed on any program are those of the persons appearing on the program and do not necessarily reflect the views and opinions of the eHealth Radio Network.

Financial toxicity’s devastating effect on people with late stage illnesses – there are solutions.

Financial toxicity’s devastating effect on people with late stage illnesses – there are solutions.

November 1, 2018

 

AdamBalinksy.jpg

 

Adam Balinsky, Founder and President of Fifth Season Financial, a financial services firm which offers solutions and products to help relieve the financial pressures faced by many patients struggling with advanced illnesses, including cancer joins eHealth Radio and the Health News Channel. Its FLAG (Funds for Living and Giving) program is designed to bridge the gap between the traditional financial assistance programs available to mitigate the direct medical and treatment costs, and the much broader financial needs of patients.

 

Listen to interview with host Eric Michaels & guest Adam Balinsky discuss the following:

  1. What is financial toxicity and how does it impact your clients?
  2. What’s the difference between your FLAG program and viatical settlements?
  3. Why aren’t nonprofits and hospitals talking about this option when it comes to people who are dealing with late stage illnesses?
  4. Is there a personal story behind FSF that you can share?
  5. What’s the thing your most proud of when it comes to your business?

 

Adam Balinsky is the Founder and President of Fifth Season Financial. He passionately believes in the mission of the company—to help relieve the financial pressures faced by many patients struggling with advanced illnesses including cancer.

Adam recognizes that people facing advanced-stage diseases have incremental financial pressures affecting everyday life that are not being addressed. That’s why Fifth Season’s financial assistance program, FLAG (Funds for Living and Giving), is designed to bridge the gap between the traditional financial assistance programs available to mitigate the direct medical and treatment costs, and the much broader financial needs of patients. The FLAG Program provides patients with money from a non-traditional asset – their existing life insurance policy.

Adam hopes that those who use our financial assistance program are able to use the funds to maintain or better their quality of life. The funds can be used as the patient sees fit. Common uses include paying rent or mortgage bills, utility bills, medication costs, treatment costs. Others use the funds to take a dream trip—creating lasting memories with family members, to pay for in-home care, or to pay to bring family together. To date, Fifth Season has assisted nearly 400 patients and their families and provided more than $75 million in financial help to patients with advanced illnesses.

The Story Behind Adam’s Passion for Fifth Season’s Services

A year after Adam and his family moved to the United States from Canada, his wife, Tracey, was diagnosed with breast cancer. While dealing with the sobering realities of their new situation, Adam began to learn about the many ways organizations in the U.S. support patients medically and emotionally. However, he was disappointed to see the very limited structured support for the broad range of financial strains patients often face. Adam was motivated and inspired to proactively do something about it. After serving as director of Fifth Season Financial from 2007 through 2009, Adam acquired Fifth Season Financial in October 2012. He then structured and developed the FLAG program to specifically address financial needs of people facing advanced-stage illnesses. Beyond Fifth Season, Adam and Tracey (who is now five years post treatment and doing very well!) are very active in supporting cancer causes, including Gilda’s Club Westchester, where Tracey is a member of the Board of Directors.

Adam’s Expertise

Adam is a lawyer by training, having practiced law for 11 years at Baker & McKenzie LLP, where he became a partner in 2005. Adam holds a joint MBA/JD from the University of Toronto and a Bachelors of Commerce from McGill University. He is admitted to practice law in the Province of Ontario, Canada, and is in good standing with the American Bar Association and the Law Society of Upper Canada. He has served on the Board of Directors of the Life Insurance Settlement Association (LISA) from May 2011 to May 2013.

 

Fifth_Season_Logo.jpg

 

Website: www.fifthseasonfinancial.com

Social Media Links:
Facebook: facebook.com/5SeasonFin
Twitter: @5SeasonFin
LinkedIn: linkedin.com/company/fifth-season-financial-assistance

Dr. David Samadi on the Future of Cancer Care

Dr. David Samadi on the Future of Cancer Care

April 7, 2018

 

DavidSamadi_2.jpg

 

Dr. David Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital and the inventor of the “Samadi Modified Advanced Robotic Technique,” a minimally invasive robotic-assisted laparoscopic prostatectomy joins eHealth Radio and the Cancer Prevention and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Dr. David Samadi discuss the following:

  1. What are some of the unique and different skills you have, as a doctor?
  2. How do you interact positively with support staff?
  3. How do you remain current in your medical training?
  4. How do you encourage patients to proactively manage their health and improve their habits?

 

Dr. David Samadi was born in Iran in 1964. He was forced to leave the Jewish community he was raised in because the country became embroiled in the Iranian Revolution in 1979. At the age of 15, Dr. Samadi made his way to Belgium and then London with his younger brother. When he was able to finally make it to the United States, he entered high school in Roslyn, New York.

After he graduated from high school, Dr. Samadi attended Stony Brook University where he studied for a degree in biochemistry on a full scholarship. He attended Stony Brook School of Medicine and received his M.D. degree in 1994. While he was at Montefiore Medical Center, Dr. Samadi received training in urology. He obtained his training in proctology at Albert Einstein College of Medicine and Montefiore Medical Center.

In 2001, Dr. Samadi finished his oncology fellowship in the area of proctology while he was at Memorial Sloan Kettering Cancer Center. In 2002, he traveled to France to study at Henri Mondor Hospital Creteil where he undertook a radical prostatectomy fellowship. During this time, he studied under Professor Claude Abbou.

Dr. Samadi invented his own robotic technique for performing prostatic surgery, and he called it “Samadi Modified Advanced Robotic Treatment” or SMART. Ordinarily, this type of cancer is known to be extremely deadly, but when Dr. Samadi used his SMART technique to treat his patients, nearly 90 percent of them could be declared to be free of cancer.

Because of his dramatic success as a surgeon, New York Magazine put his name on its “Best Doctors List.” His name is also on the Castle Connolly “America’s Top Doctors List.”

 

DavidSamadi_LOGO.jpg

 

Website: http://samadimd.com  | http://prostatecancer911.com

Social Media Links:
Facebook: https://www.facebook.com/DrDavidSamadi
Twitter: https://twitter.com/drdavidsamadi

VCA offers most advanced technology to treat animals with cancer

VCA offers most advanced technology to treat animals with cancer

March 20, 2018

 

Custis_2.jpg

 

Veterinary specialist, Dr. James T. Custis, III, Radiation Oncologist, who practices at the VCA Animal Diagnostic Clinic in Dallas, Texas joins eHealth Radio & the Animal Health Channel to discuss how VCA offers the most advanced technology to treat animals with cancer.

 

Listen to interview with host Eric Michaels & guest Dr. James T. Custis discuss the following:

  1. As a veterinary radiation oncologist at VCA’s Animal Diagnostic Clinic, can you share some background on why you chose to specialize in veterinary oncology and some of the advanced educational and training requirements that are needed for this specialty? 
  2. Can you tell us about VCA Animal Diagnostic Clinic’s state-of-the art TrueBeam Radiotherapy System and how it is used to diagnose and treat pet cancer?
  3. What types of cancers can be treated with this technology and what are the benefits for pet patients and their families?
  4. It appears that VCA is on the forefront of veterinary oncology with the latest tools and techniques to treat even the most challenging cancer cases. Are there many other facilities that offer this type of advanced technology and multi-disciplinary approach to pet cancer?
  5. When a pet is being treated for cancer, what should pet parents expect during and after treatment?
  6. In addition to advanced technologies like the TrueBeam, what other innovative tools and techniques are you aware of that are being developed to treat pet cancer in the future?

 

Dr. Custis received his DVM from Virginia-Maryland Regional College of Veterinary Medicine in 2005. During his two years in a progressive small animal practice in Houston, Texas, he developed a particular interest in oncology. Thus, he then pursued a one-year small animal medicine and surgery internship at Carolina Veterinary Specialists in Greensboro, North Carolina. Subsequently, he completed a dual program consisting of a Master of Science in Radiological Health Sciences, and a residency in veterinary radiation oncology at Colorado State University Flint Animal Cancer Center. He became board certified in Radiation Oncology by the American College of Veterinary Radiology in 2011. During his residency training at the Colorado State University Flint Animal Cancer Center, Dr. Custis became proficient in the utilization of new modalities such as intensity modulated radiation therapy (IMRT) and stereotactic radiation therapy (SRT) in an effort to improve local tumor control and decrease normal tissue side effects. Dr. Custis remained on faculty at Colorado State University until joining our team in 2015. His research interest's center upon the treatment of spontaneously occurring tumors in client owned animals with an emphasis upon the potential translational applications and the benefits of radiation therapy.

In his spare time, Dr. Custis enjoys the outdoors, golf, and running with his canine companion, Huckleberry.

About VCA Animal Diagnostic Clinic

VCA Animal Diagnostic Clinic provides veterinarians, along with their clients and pets, with the highest quality diagnostic and therapeutic care as it relates to internal medicine, oncology and cardiology.

 Located in Dallas, Texas, specialists and technicians are trained to the highest standards. Their thorough knowledge of the latest procedures and medicines ensures that patients receive the best care available. One such advancement is the state-of-the-art TruebeamTM radiation technology that can deliver better, safer and faster radiation treatment with unmatched precision to tumors.

At the heart of VCA’s advanced care services are board-certified veterinarian specialists, who have access to extensive medical resources, not the least of which is the VCA knowledge base, which allows doctors to tap into the collected knowledge of over 4,000 VCA veterinarians.


 

VCAlogo_2.jpg

 

Website: https://vcahospitals.com/animal-diagnostic-clinic-dallas/services

Social Media Links:
Facebook: https://Facebook.com/VCAAnimalHospitals
Twitter: https://Twitter.com/VCAPetHealth

VCA, offering multidisciplinary approach and advanced technology to treat animals with cancer

VCA, offering multidisciplinary approach and advanced technology to treat animals with cancer

March 14, 2018

 

ZacharyWright_MED.jpg

 

Dr. Zachary Wright, DVM, the Director of Oncology at VCA Animal Diagnostic Clinic in Dallas, Texas joins eHealth Radio and the Animal Health Channel to discuss how VCA is offering multidisciplinary approach and advanced technology to treat animals with cancer.

 

Listen to interview with host Eric Michaels & guest Dr. Zachary Wright discuss the following:

  1. As director of oncology for VCA Animal Diagnostic Clinic in Dallas, Texas, can you tell us about the Animal Diagnostic Clinic and why this oncology practice is of growing importance today for pets and their families?
  2. As a veterinary medical oncologist, can you share some background on why you chose veterinary oncology and what the educational requirements are for this specialty? 
  3. How does VCA Animal Diagnostic Clinic approach diagnosing and treatment for pet cancer? What sets it apart from other veterinary hospitals and can you explain a little about the Triad of Care?
  4. What are some of the latest technologies and tools available at your clinic for the treatment of pets with cancer?
  5. In human medicine, we hear a lot about clinical trials and how they can evaluate cutting edge cancer testing and treatments. How does VCA’s participation in clinical trials benefit pets and cancer outcomes?
  6. When a pet parent is facing a diagnosis of cancer for their family pet, what advice can you offer to them to help them through the process?

 

Dr. Zachary Wright was raised in the DFW Area (Rockwall). He received his Bachelor of Arts degree in History from the University of Notre Dame and his veterinary medical degree from Texas A&M University, College of Veterinary Medicine in 2004. He then completed a one year rotating small animal internship in medicine and surgery at VCA West Los Angeles Animal Hospital in Los Angeles, California. Dr. Wright followed his passion in pursuing a residency in small animal oncology at Texas A&M University and became a Diplomate of the American College of Veterinary Internal Medicine-Oncology in 2008.



Upon completion of his residency, Dr. Wright joined the staff at VCA Veterinary Care in Albuquerque, New Mexico, to open a new oncology practice. While on staff he served as director of the internship program. In 2012 Dr. Wright and his family were thrilled with the opportunity to move back to North Texas and join VCA Animal Diagnostic Clinic where he now serves as Director of Oncology.



Dr. Wright has published numerous scientific articles and book chapters in small animal oncology. He also lectures to veterinarians across the United States. He believes in giving back to his profession and has served in multiple roles within his regulatory college, the American College of Veterinary Medicine, including positions on the Board of Regents.



As a clinical oncologist, Dr. Wright believes in fully educating his clients on the nature of their pet’s cancer. A cancer diagnosis is rarely a black and white topic and he believes in making sure there are multiple diagnostic and treatment options for all his patients regardless of the situation. Additionally, he is passionate about the role of the veterinary oncologist in palliative care of pets with cancer. At VCA Animal Diagnostic Clinic, Dr. Wright has proactively brought a collection of clinical trials to our hospital that evaluate cutting edge cancer testing and treatments. He believes in the Triad of Care and working as a team with your primary care veterinarian to ensure all his patients receive optimal care.



Dr. Wright and his wife (also a veterinarian in Dallas) have two young boys and their rescue dog Allie. In his free time, he enjoys spending time with his children, the Dallas restaurant scene, golfing and fly fishing.

About VCA Animal Diagnostic Clinic

VCA Animal Diagnostic Clinic provides veterinarians, along with their clients and pets, with the highest quality diagnostic and therapeutic care as it relates to internal medicine, oncology and cardiology. 

Located in Dallas, Texas, specialists and technicians are trained to the highest standards. Their thorough knowledge of the latest procedures and medicines ensures that patients receive the best care available. One such advancement is the state-of-the-art TruebeamTM radiation technology that can deliver better, safer and faster radiation treatment with unmatched precision to tumors.

At the heart of VCA’s advanced care services are board-certified veterinarian specialists, who have access to extensive medical resources, not the least of which is the VCA knowledge base, which allows doctors to tap into the collected knowledge of over 4,000 VCA veterinarians.


 

VCA_logo.jpg

 

Website: https://vcahospitals.com

Social Media Links:
Facebook: https://www.facebook.com/VCAAnimalHospitals
Twitter: https://twitter.com/VCAPetHealth
Linkedin: https://www.linkedin.com/company/vca-

Play this podcast on Podbean App